Relationship between molecular pathology of tumors and radiobiological parameters

肿瘤分子病理学与放射生物学参数的关系

• 批准号: 11670921
• 负责人: NISHIMURA Yasumasa
• 金额: $ 2.3万
• 依托单位: Kinki Univ.
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1999
• 资助国家: 日本
• 起止时间: 1999 至 2000
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-11670921/
• 关键词: quiescent cells; radioresistance; cell cycle docetaxel; recruitment; erythropoietin; VEGF; angiogenesis; 放射線生物学; Ki-67標識率; PCNA標織率; G0細胞分画; 細胞周期; Docetaxel; Mild hyperthermia

The effect of docetaxel, which stops the cycling cells at G2/M boundary, on recruitment from G0 phase to cycling phase was investigated in vivo using SCCVII tumor of C3H/He mice. G0 fraction at 24, 48, 72, 120, h after administration of docetaxel (90 mg/kg) was measured by flow cytometry and anti-Ki-67 labeling methods. Decrease of G1 fraction and increase of G2/M fraction were evident 24 h and 48 h after treatment. On the other hand, G0 fraction did not change until 120 h. The present study indicates that docetaxel inhibits recruitment from G0 to cycling cells in a solid tumor.The role of erythropoietin (EPO) in angiogenesis of rat liver tumors was investigated using immunohistochemical methods. EPO-receptor was detected in liver tumors, although it was not detected in normal and cirrhotic hepatic cells. In addition, significant correlation was noted between intratumor EPO concentration and microvascular density of the tumor. The present study suggests that EPO is related to the angiogenesis of malignant hepatic tumors.

使用C3 H/He小鼠的SCCVII肿瘤在体内研究了多西他赛（其在G2/M边界停止细胞周期）对从G 0期募集到周期期的影响。采用流式细胞术和抗Ki-67标记法测定多西他赛（90 mg/kg）给药后24、48、72、120 h的G 0期细胞比例。处理后24 h和48 h，G1期细胞比例明显下降，G2/M期细胞比例明显上升。另一方面，G 0分数直到120 h才发生变化。本研究采用免疫组织化学方法研究了多西他赛抑制实体瘤中G 0期细胞向周期细胞募集的作用，探讨了促红细胞生成素（EPO）在大鼠肝癌血管生成中的作用。EPO受体在肝肿瘤中被检测到，而在正常肝细胞和肝硬化肝细胞中未检测到。此外，肿瘤内EPO浓度与肿瘤微血管密度之间存在显著相关性。本研究提示EPO与肝恶性肿瘤的血管生成有关。

项目成果

Kokubo M,Nishimura Y, 他: "Analysis of the clinical benefit of intraoperative radiotherapy in patients undergoing macroscopically curative resection for pancreatic cancer."Int.J.Radiat.Oncol.Biol.Phys.. 48. 1081-1087 (2000)

Kokubo M、Nishimura Y 等人：“接受宏观治愈性胰腺癌切除术的患者术中放疗的临床益处分析。Int.J.Radiat.Oncol.Biol.Phys.. 48. 1081-1087 (2000) ）

Nishimura Y., et al.: "Long-term results of fractionated Strontium-90 radiation therapy for pterygia."Int.J.Radiat.Oncol.Biol.Phys.. 46. 137-141 (2000)

Nishimura Y. 等人：“分次锶 90 放射治疗翼状胬肉的长期结果。”Int.J.Radiat.Oncol.Biol.Phys.. 46. 137-141 (2000)

Nemoto K,Nishimura Y, 他: "Treatment of superficial esophageal cancer by external radiation therapy alone : results of a multi-institutional experience."Int.J.Radiat.Oncol.Biol.Phys.. 46. 921-925 (2000)

Nemoto K、Nishimura Y 等人：“仅通过外部放射治疗治疗浅表性食管癌：多机构经验的结果。”Int.J.Radiat.Oncol.Biol.Phys.. 46. 921-925（ 2000)

Horii N, Nishimura Y, et al.: "Impact of neoadjuvant chemotherapy on Ki-67 and PCNA labeling indices for esophageal squamous cell carcinomas."Int.J.Radiat.Oncol.Biol.Phys.. (in press).

Horii N、Nishimura Y 等人：“新辅助化疗对食管鳞状细胞癌 Ki-67 和 PCNA 标记指数的影响”。Int.J.Radiat.Oncol.Biol.Phys.（出版中）。

Okuno Y.,Nishimura Y.,他: "Prognostic values of proliferating cell nuclear antigen(PCNA)and Ki-67 for definitive radiotherapy of esophageal squamous cell carcinomas"Br.J.Cancer. 80. 387-395 (1999)

Okuno Y.、Nishimura Y. 等人：“增殖细胞核抗原 (PCNA) 和 Ki-67 对食管鳞状细胞癌根治性放疗的预后价值”Br.J.Cancer. 80. 387-395 ( 1999）